Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory. 2000

R V Fornari, and K M Moreira, and M G Oliveira
Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), Rua Napoleão de Barros 925 CEP 04024-002, São Paulo SP, Brazil.

The nonselective muscarinic antagonist scopolamine is known to impair the acquisition of some learning tasks such as inhibitory avoidance. There has been recent research into the effects of this drug in contextual fear conditioning and tone fear conditioning paradigms. The purpose of the present study was to assess the role of the selective M1 muscarinic antagonist dicyclomine in these paradigms and in the inhibitory avoidance test. Rats were administered different doses of dicyclomine or saline 30 min before acquisition training. The animals were tested 24 hr later, and it was observed that 16 mg/kg of dicyclomine impaired both contextual fear conditioning and inhibitory avoidance. However, dicyclomine (up to 64 mg/kg) did not affect tone fear conditioning. These results suggest that the selective M1 muscarinic antagonist dicyclomine differentially affects aversively motivated tasks known to be dependent on hippocampal integrity (such as contextual fear conditioning and inhibitory avoidance) but does not affect similar hippocampus-independent tasks.

UI MeSH Term Description Entries
D008297 Male Males
D008568 Memory Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
D011930 Reaction Time The time from the onset of a stimulus until a response is observed. Response Latency,Response Speed,Response Time,Latency, Response,Reaction Times,Response Latencies,Response Times,Speed, Response,Speeds, Response
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D003213 Conditioning, Psychological Simple form of learning involving the formation, strengthening, or weakening of an association between a stimulus and a response. Conditioning, Psychology,Psychological Conditioning,Social Learning Theory,Social Learning Theories,Theory, Social Learning
D004025 Dicyclomine A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. Dicycloverin,Bentyl,Bentylol,Di-Cyclonex,Di-Spaz,Dibent,Diclomin,Dicyclomine Hydrochloride,Lomine,Merbentyl,OR-Tyl,Spascol,Di Cyclonex,Di Spaz,Hydrochloride, Dicyclomine,OR Tyl
D004644 Emotions Those affective states which can be experienced and have arousing and motivational properties. Feelings,Regret,Emotion,Feeling,Regrets
D000161 Acoustic Stimulation Use of sound to elicit a response in the nervous system. Auditory Stimulation,Stimulation, Acoustic,Stimulation, Auditory
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000924 Anticholesteremic Agents Substances used to lower plasma CHOLESTEROL levels. Cholesterol Inhibitors,Hypocholesteremic Agents,Anticholesteremic Drugs,Anticholesteremics,Inhibitors, Cholesterol,Agents, Anticholesteremic,Agents, Hypocholesteremic,Drugs, Anticholesteremic

Related Publications

R V Fornari, and K M Moreira, and M G Oliveira
February 2016, Behavioral neuroscience,
R V Fornari, and K M Moreira, and M G Oliveira
September 1986, British journal of pharmacology,
R V Fornari, and K M Moreira, and M G Oliveira
March 1993, The European respiratory journal,
R V Fornari, and K M Moreira, and M G Oliveira
January 2000, Brain research,
R V Fornari, and K M Moreira, and M G Oliveira
July 2008, Brain research bulletin,
R V Fornari, and K M Moreira, and M G Oliveira
October 1993, The Journal of pharmacology and experimental therapeutics,
R V Fornari, and K M Moreira, and M G Oliveira
June 2016, The Journal of biological chemistry,
R V Fornari, and K M Moreira, and M G Oliveira
January 1992, Respiration; international review of thoracic diseases,
R V Fornari, and K M Moreira, and M G Oliveira
July 1997, Neuroscience letters,
R V Fornari, and K M Moreira, and M G Oliveira
April 1994, Pulmonary pharmacology,
Copied contents to your clipboard!